Physician profile
Vy Pham
NPI 1669185195
$1,393.31
in general payments reported to CMS, 2019-2025
10 companies · $481 in 2025
The $481 reported for 2025 was more than what 76% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $365 · 2024: $548 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,273 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,273.32 |
| Education | $119.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $426.61 | 2023-2025 | Terlivaz |
| Gilead Sciences, INC. | $159.39 | 2024-2025 | Livdelzi |
| Astellas Pharma US INC | $152.66 | 2024 | Cresemba |
| Edwards Lifesciences Corporation | $144.25 | 2023 | Hemosphere |
| Ipsen Biopharmaceuticals, INC | $124.95 | 2024 | Iqirvo |
| Novo Nordisk INC | $120.25 | 2025 | Wegovy |
| Madrigal Pharmaceuticals | $113.91 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $95.63 | 2023 | Ocaliva |
| Veloxis Pharmaceuticals, INC. | $35.03 | 2024 | Envarsus |
| Csl Behring | $20.63 | 2024 | Kcentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vy Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.